ASH Annual Meeting and Exposition | Conference

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

December 8th 2019

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Acalabrutinib Triplet Highly Active in Frontline CLL

December 8th 2019

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL

December 8th 2019

With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.

Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL

December 8th 2019

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

December 8th 2019

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma

December 8th 2019

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

Novel Antibody Elicits Complete Remissions in NHL After CAR Relapses

December 8th 2019

Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

December 7th 2019

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL

December 7th 2019

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

December 7th 2019

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Fate Touts Novel Off-the-Shelf Cell Therapy

December 7th 2019

An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.

Landgren Previews Pivotal ASH 2019 Myeloma Data

December 6th 2019

Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

December 11th 2018

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL

December 5th 2018

The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.

Competition Grows in Anti-BCMA CAR Pipeline for Multiple Myeloma

December 5th 2018

A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.

Mutation in BCL2 Protein Confers Resistance to Venetoclax

December 4th 2018

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma

December 4th 2018

The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Rivaroxaban May Reduce Blood Clot Risk During Active Systemic Cancer Therapy

December 4th 2018

Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.

High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL

December 4th 2018

Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.